Association Review
In brief
The association between NRAS (NRAS Proto-Oncogene, GTPase) and Esophageal Cancer is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
17
Compounds
5
Trials
237of 8,634 via NRAS compounds
Publications
0
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Esophageal Cancer
The disorder
40 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Phenotype
Clinical features
1 clinical feature
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access
06
Interventions
Therapeutics
5 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials
8,634 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
08
Provenance
References & sources
8 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access